NASDAQ · AKTX
Akari Therapeutics, Plc
$8.40+$0.40 (+5.0%)
Akari Therapeutics, Plc’s quoted price sits in the lower half of its reported 52-week range, 75.0% below the high.
Loading market information…
OTC · FOXO · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
FOXO Technologies Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.17% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow FOXO Technologies Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
FOXO Technologies Inc. operates as a technology platform company primarily focused on translating longevity science into practical applications for the life insurance sector. The firm is actively creating products and services that integrate scientific understanding of longevity with life insurance offerings. The dual objectives of these innovations are to encourage greater consumer involvement in their health and wellness, and to streamline the often-complex insurance underwriting process for customers. Among its key offerings is FOXO Labs, a service-oriented platform that enhances the customer underwriting experience by incorporating saliva-based epigenetic biomarkers into expedited underwriting procedures. Additionally, the company provides FOXO Life, an insurance products platform. This platform offers a combination of FOXO's own unique life insurance products and policies from third-party carriers, all designed to bundle longevity science with life insurance. FOXO Technologies Inc. was established in 2019 and is headquartered in Minneapolis, Minnesota.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:41 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$8.40+$0.40 (+5.0%)
Akari Therapeutics, Plc’s quoted price sits in the lower half of its reported 52-week range, 75.0% below the high.
$4.20+$0.00 (+0.01%)
P3 Health Partners Inc.’s quoted price sits in the lower half of its reported 52-week range, 75.13% below the high.
$1.99+$0.02 (+1.02%)
Aclarion, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.74% below the high.
$0.83-$0.01 (-1.47%)
Dermata Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 82.22% below the high.
$3.65-$0.10 (-2.67%)
Revelation Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 91.01% below the high.
$0.02$0.00 (0.0%)
Vincerx Pharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.95% below the high.
$0.15+$0.00 (+2.6%)
Silexion Therapeutics Ltd.’s quoted price sits in the lower half of its reported 52-week range, 99.56% below the high.
$0.00$0.00 (0.0%)
Syros Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.0% below the high.
